Hyperfine Reports Lower Q1 Revenue, $9.4M Net Loss Amid Cost Cuts

Hyperfine, Inc. reported first quarter 2025 revenue of approximately $2.1 to $2.14 million, falling short of analyst expectations around $2.8 million, primarily due to decreased sales of its Swoop portable MRI systems amid prolonged and variable hospital sales cycles. Despite this, the company has advanced its commercial pipeline, including promising opportunities in neurology office settings, and has begun commercialization efforts in Canada, Europe, Australia, and New Zealand with regulatory approvals secured. The net loss for the quarter was $9.4 million, or $0.12 per share, an improvement from prior year losses, supported by cost reductions and a $6 million capital raise extending operational runway through 2026. Hyperfine anticipates accelerated growth starting in the second half of 2025, driven by expected FDA clearances for next-generation portable brain MRI systems that aim to set new image quality standards. Analysts maintain an "Outperform" consensus with price targets averaging around $1.30, signaling significant upside potential from the current stock price near $0.70. The company continues to invest in research and development, including ongoing AI-powered portable MRI studies, with a focus on diversifying revenue streams beyond hospitals into neurology offices.